Literature DB >> 7457471

Impact of epidemic type A influenza in a defined adult population.

W H Barker, J P Mullooly.   

Abstract

The authors studied the occurrence of excess morbidity and mortality among subsets of the adult population (persons over 14 years of age) of a large prepaid group practice during two epidemics of type A influenza (1968-1969 and 1972-1973). The experience from 1970-1971, a nonepidemic years, was used as a reference for estimating excesses. Ambulatory visits for influenza and influenza-related acute respiratory disease increased by 5-7 visits per 100 persons (30-50% excess) and pneumonia and influenza (P&I) hospitalization rates increased by 79-86 per 100,000 (140-150% excess) over the rates in the nonepidemic period. There were 11-13 excess deaths per 100,000 population, most of which involved persons over 65 years of age. Excess rates of ambulatory visits were similar for all adult age groups. Excess rates of persons hospitalized with P&I ranged from 23-25 per 100,000 among non-high risk persons aged 15-44 years to 150-172 per 100,000 among persons over age 65 years without underlying "high risk" conditions and 476-636 per 100,000 persons over 65 with underlying "high risk" conditions. These data provide a basis for increasing the precision of clinical and public decision-making regarding the prevention of serious consequences of epidemic influenza.

Entities:  

Mesh:

Year:  1980        PMID: 7457471     DOI: 10.1093/oxfordjournals.aje.a113052

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  88 in total

1.  Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective.

Authors:  S C Wood; V H Nguyen; C Schmidt
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

2.  Influenza vaccine match with circulating strains and indicators of influenza strain impact - Canada 1980 to 1992.

Authors:  E Ellis; J M Weber; W Cuff; S G Mackenzie
Journal:  Can J Infect Dis       Date:  1998-05

3.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Authors:  D C Powers; L F Fries; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

4.  Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice.

Authors:  Katsuhiko Hayashi; Shin-etsu Kadowaki; Masaya Takei; Hideyuki Fukuda
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.

Authors:  Michael Kurowski; Charles Oo; Hugh Wiltshire; Joanne Barrett
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 6.  KLRG1--more than a marker for T cell senescence.

Authors:  Sian M Henson; Arne N Akbar
Journal:  Age (Dordr)       Date:  2009-12

7.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

8.  Antibody and CD8+ T cell memory response to influenza A/PR/8/34 infection is reduced in treadmill-exercised mice, yet still protective.

Authors:  Kristi Warren; Nicholas Thompson; Michael Wannemuehler; Marian Kohut
Journal:  J Appl Physiol (1985)       Date:  2013-03-14

9.  Influenza-associated cystic fibrosis pulmonary exacerbations.

Authors:  Justin R Ortiz; Kathleen M Neuzil; John C Victor; Anna Wald; Moira L Aitken; Christopher H Goss
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

10.  Humoral and cellular immune responses to influenza vaccination in children with cancer receiving chemotherapy.

Authors:  Rosa María Wong-Chew; Margarita Nava Frías; Miguel Leonardo García-León; Lourdes Arriaga-Pizano; Aurora Medina Sanson; Constantino Lopez-Macías; Armando Isibasi; José Ignacio Santos-Preciado
Journal:  Oncol Lett       Date:  2012-05-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.